Method of treatment and devices for the treatment of left ventricular failure

• US 20060074483A1
• Filed: 10/01/2004
• Published: 04/06/2006
• Est. Priority Date: 10/01/2004
• Status: Abandoned Application

• Current Assignee: Howard L. Schrayer
• Original Assignee: Howard L. Schrayer
• Inventors: Schrayer, Howard L.
• Application Number:
  US10/957,436
• Publication Number:
  US 20060074483A1
• Time in Patent Office: Days
• US Class Current: 623/2.100
• CPC Class Codes: A61B 2017/22001 Angioplasty, e.g. PCTA
• CPC Class Codes: A61B 2017/22038 with a guide wire
• CPC Class Codes: A61F 2/2412 with soft flexible valve members, e.g. tissue valves shaped like natural valves check valves with flexible valve members in general F16K15/14
• CPC Class Codes: A61F 2/2475 Venous valves
• CPC Class Codes: A61F 2250/0059 temporary
• CPC Class Codes: A61M 29/02 Dilators made of swellable material balloon catheters for angioplasty A61M25/104

Abstract

The effects of acute left ventricular heart failure are mitigated by temporary support of the cardiac function through use of either one or both of an expendable temporary one-way valve positioned in the aorta, having a collapsible frame that is expanded upon deployment, and/or a temporary dilation device positioned in the descending aorta for expanding upon deployment to increase the diameter of the associated portion of the aorta. When used together, the dilation device is positioned distal to the temporary one-way valve.

Claims

1. A method for mitigating the effects of left ventricular heart failure, by temporary support of cardiac function comprising the steps of:

a) providing via percutaneous transluminal introduction an expandable temporary one-way valve having a valve support frame;

b) positioning the valve at a site in either one of the ascending aorta or the descending thoracic aorta downstream of the aortic arch;

c) expanding the diameter of said valve support frame so as to allow the valve to function in series with the patient'"'"'s essentially normal aortic valve, thereby allowing the temporary valve to decrease the back pressure on the natural valve when both valves are closed during the diastolic phase of the cardiac cycle; and

d) repositioning the valve at a site further downstream prior to its removal in order to gradually wean an associated patient from the temporary support of cardiac function.

2. The method of claim 1, wherein said one-way valve includes:

a) a collapsible frame having at least three wires or bands joined at least at one end and biased radially outward so as to form a generally conic or bulbous cage upon deployment;

b) a control element joined directly or indirectly to the collapsible frame members at their juncture at the apex of the frame and extending to a point outside of the body to allow expansion and collapse of the frame by alternately allowing advancement of the frame from a constraining catheter and retraction of the frame into the catheter;

c) an annulus in the form of a flexible strand disposed within or around the frame in a plane perpendicular to the longitudinal axis of the frame in the deployed position or a fluid permeable mesh disc disposed within the frame in a similar plane; and

d) at least three thin, flexible, biocompatible leaflets attached at their fixed edges to the annular strand or the mesh disc and configured to permit central flow of blood during cardiac systole and to substantially prevent retrograde flow of blood during cardiac diastole.

3. The method of claim 1, further including the step of:

incorporating remote sensing means with said temporary valve for capturing physiological data including intra arterial pressure, cardiac output, pulse rate, and other desired data.

4. A method for mitigating the effects of left ventricular heart failure, by temporary support of cardiac function comprising the steps of:

a) providing via percutaneous transluminal introduction a temporary dilation means;

b) positioning the temporary dilation means at a site in the aorta or peripheral arteries;

c) expanding the diameter of the dilation means thereby increasing the diameter of that portion of the aorta engaged by the device, for decreasing outflow resistance, while allowing the flow of blood to follow its natural course; and

d) decreasing the extent of expansion of the dilation means prior to removing the device in order to gradually wean an associated patient from the temporary support of cardiac function.

5. The method of claim 4, further including the step of:

forming said temporary dilation means via longitudinal compression of an array of wires or bands to obtain a cylinder that increases in diameter as the ends of the cylinder are moved toward each other.

6. The method of claim 4, whereby said temporary dilation means in a collapsed or unexpanded state has a diameter between 1 mm and 6 mm, and in an expanded state has a diameter between 25 mm and 50 mm.

7. The method of claim 4, whereby said expanding step allows the volume of the intravascular space occupied by said temporary dilation means to be increased by up to 200 cc.

8. A method for mitigating the effects of acute left ventricular heart failure, by temporary support of cardiac function comprising the steps of:

a) introducing into the aorta of a patient via percutaneous transluminal insertion an expandable temporary one-way valve including a valve support frame;

b) positioning the valve at a site in either one of the ascending aorta or the thoracic aorta downstream of the aortic arch;

c) expanding the diameter of said valve support frame so as to allow the valve to function in series with the patient'"'"'s essentially normal aortic valve, thereby allowing the temporary valve to decrease the back pressure on the natural valve when both valves are closed during the diastolic phase of the cardiac cycle;

d) introducing into said aorta or peripheral arteries via percutaneous transluminal insertion a temporary dilation means;

e) positioning the temporary dilation means at a site in the descending aorta downstream of the temporary valve;

f) expanding the diameter of the dilation means for increasing the diameter of the associated portion of the aorta, thereby decreasing outflow resistance, while allowing the flow of blood to follow its natural course; and

g) repositioning the valve at a site further downstream prior to removing it in order to gradually wean the patient from the temporary support of cardiac function, and/or decreasing the extent of expansion of the dilation means prior to removing it in order to gradually wean the patient from the temporary support of cardiac function.

9. Apparatus for jointly providing intravascular treatment of acute left ventricular heart failure comprising:

a) a collapsible temporary valve assembly including means for deploying it into the aorta via its introduction into the vascular system using percutaneous transluminal techniques, and means for both expanding and deploying it in the aorta; and

b) a collapsible vessel dilation assembly including means for deploying it into the aorta or peripheral arteries via its introduction into the vascular system using percutaneous transluminal techniques, and means for both expanding its diameter and deploying it in the aorta or peripheral arteries.

10. A device for the intravascular treatment of acute left ventricular heart failure comprising:

a collapsible temporary valve assembly including means for deploying it into the aorta via its introduction into the vascular system using percutaneous transluminal techniques, and means for both expanding and deploying it in the aorta.

11. A device for the intravascular treatment of acute left ventricular heart failure comprising:

a collapsible vessel dilation assembly including means for deploying it into the aorta or peripheral arteries via its introduction into the vascular system using percutaneous transluminal techniques, and means for both expanding its diameter and deploying it in the aorta or peripheral arteries.